• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ahmad Shahraab acquired 50,000 units of Series A Common Stock and disposed of 50,000 units of Series A Common Stock (SEC Form 4)

    11/8/23 4:15:15 PM ET
    $ACAB
    Blank Checks
    Finance
    Get the next $ACAB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Ahmad Shahraab

    (Last) (First) (Middle)
    49 CATHCART ROAD

    (Street)
    LONDON X0 SW10 9JE

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Atlantic Coastal Acquisition Corp. II [ ACAB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    Chairman and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    11/06/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Series A Common Stock, par value $0.0001 per share 11/06/2023 J(1) 50,000 A (1) 7,249,999 I See Footnote(3)
    Series A Common Stock, par value $0.0001 per share 11/07/2023 J(2) 50,000 D (1) 7,199,999 I See Footnote(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Ahmad Shahraab

    (Last) (First) (Middle)
    49 CATHCART ROAD

    (Street)
    LONDON X0 SW10 9JE

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Atlantic Coastal Acquisition Management II LLC

    (Last) (First) (Middle)
    6 ST JOHNS LANE, FLOOR 5

    (Street)
    NEW YORK NY 10013

    (City) (State) (Zip)
    Explanation of Responses:
    1. On November 6, 2023, Iqbaljit Kahlon resigned from the Board of Directors of Atlantic Coastal Acquisition Corp. II (the "Company"). Pursuant to the terms of Mr. Kahlon's stock grant from the Company, Mr. Kahlon's resignation triggered a forfeiture of 50,000 shares of Series A Common Stock then-held by Mr. Kahlon to Atlantic Coastal Acquisition Management II LLC, the Company's initial public offering sponsor (the "Sponsor").
    2. On November 6, 2023, Curtis Collar was appointed to the Board of Directors of the Company. On November 7, 2023, in connection with Mr. Collar's appointment, Mr. Collar received a grant of 50,000 shares of Series A Common Stock then-held by the Sponsor.
    3. The Sponsor is the record holder of the securities reported herein. Shahraab Ahmad is the managing member of the Sponsor and has sole voting and investment discretion with respect to the securities held of record by the Sponsor. Mr. Ahmad disclaims any beneficial ownership of the securities held by the Sponsor.
    Remarks:
    Atlantic Coastal Acquisition Management II LLC, /s/ Shahraab Ahmad, Managing Member 11/08/2023
    /s/ Shahraab Ahmad 11/08/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ACAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atlantic Coastal Acquisition Corp. II Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

      NEW YORK, June 13, 2024 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB) (the "Company"), a special purpose acquisition company, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on June 3, 2024 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2024 (the "10-Q") with the Securities and Exchange Commission (the "SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company

      6/13/24 4:15:00 PM ET
      $ACAB
      Blank Checks
      Finance
    • Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II

      WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition company ("Atlantic Coastal"), today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination. Upon the closing of the proposed business

      1/22/24 8:00:00 AM ET
      $ACAB
      Blank Checks
      Finance
    • Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II

      Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases. The transaction values Abpro at $725 million and will help advance Abpro's drug pipeline to clinical trials. Abpro Corporation ("Abpro"), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition corporation ("Atlantic Costal"), today announced a term sheet to enter into a definitive business combination, which was entered into o

      9/21/23 4:00:00 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Atlantic Coastal Acquisition Corp. II

      NT 10-Q - Abpro Holdings, Inc. (0001893219) (Filer)

      11/15/24 4:05:03 PM ET
      $ACAB
      Blank Checks
      Finance
    • Atlantic Coastal Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Abpro Holdings, Inc. (0001893219) (Filer)

      11/13/24 5:21:02 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form 25-NSE filed by Atlantic Coastal Acquisition Corp. II

      25-NSE - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      11/12/24 4:31:03 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Abpro Bio International, Inc. claimed ownership of 16,507,334 shares (SEC Form 3)

      3 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/18/24 9:00:34 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form 3 filed by new insider Mcdonald Ian

      3 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/18/24 8:52:41 PM ET
      $ACAB
      Blank Checks
      Finance
    • Co-CEO & Chairman Suk Jin Wook (Miles) was granted 91,900 shares (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      11/15/24 9:34:52 PM ET
      $ACAB
      Blank Checks
      Finance

    $ACAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Atlantic Coastal Acquisition Corp. II (Amendment)

      SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      2/7/24 1:53:24 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Atlantic Coastal Acquisition Corp. II (Amendment)

      SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      1/19/24 4:17:41 PM ET
      $ACAB
      Blank Checks
      Finance
    • SEC Form SC 13D filed by Atlantic Coastal Acquisition Corp. II

      SC 13D - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

      4/20/23 6:01:50 AM ET
      $ACAB
      Blank Checks
      Finance